Radiation and Anti-Cancer Vaccines: A Winning Combination

被引:25
作者
Cadena, Alexandra [1 ]
Cushman, Taylor R. [1 ]
Anderson, Clark [2 ]
Barsoumian, Hampartsoum B. [3 ]
Welsh, JamesW. [3 ]
Cortez, Maria Angelica [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA
[2] Texas Tech Univ, Hlth Sci Ctr El Paso, Paul L Foster Sch Med, El Paso, TX 79415 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA
关键词
radiotherapy; in situ vaccine; cancer; immunotherapy; viral vaccines; protein/peptide vaccines; toll-like receptors; CELL LUNG-CANCER; PEPTIDE VACCINE; LOCAL RADIATION; RECURRENT GLIOBLASTOMA; ANTITUMOR-ACTIVITY; SUPPRESSOR-CELLS; PROSTATE-CANCER; TLR7; AGONIST; NECK-CANCER; P53; GENE;
D O I
10.3390/vaccines6010009
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The emerging combination of radiation therapy with vaccines is a promising new treatment plan in the fight against cancer. While many cancer vaccines such as MUC1, p53 CpG oligodeoxynucleotide, and SOX2 may be great candidates for antitumor vaccination, there still remain many investigations to be done into possible vaccine combinations. One fruitful partnership that has emerged are anti-tumor vaccines in combination with radiation. Radiation therapy was previously thought to be only a tool for directly or indirectly damaging DNA and therefore causing cancer cell death. Now, with much preclinical and clinical data, radiation has taken on the role of an in situ vaccine. With both cancer vaccines and radiation at our disposal, more and more studies are looking to combining vaccine types such as toll-like receptors, viral components, dendritic-cell-based, and subunit vaccines with radiation. While the outcomes of these combinatory efforts are promising, there is still much work to be covered. This review sheds light on the current state of affairs in cancer vaccines and how radiation will bring its story into the future.
引用
收藏
页数:8
相关论文
共 51 条
[1]   Topical TLR7 Agonist Imiquimod Can Induce Immune-Mediated Rejection of Skin Metastases in Patients with Breast Cancer [J].
Adams, Sylvia ;
Kozhaya, Lina ;
Martiniuk, Frank ;
Meng, Tze-Chiang ;
Chiriboga, Luis ;
Liebes, Leonard ;
Hochman, Tsivia ;
Shuman, Nicholas ;
Axelrod, Deborah ;
Speyer, James ;
Novik, Yelena ;
Tiersten, Amy ;
Goldberg, Judith D. ;
Formenti, Silvia C. ;
Bhardwaj, Nina ;
Unutmaz, Derya ;
Demaria, Sandra .
CLINICAL CANCER RESEARCH, 2012, 18 (24) :6748-6757
[2]   Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer [J].
Antonia, SJ ;
Mirza, N ;
Fricke, I ;
Chiappori, A ;
Thompson, P ;
Williams, N ;
Bepler, G ;
Simon, G ;
Janssen, W ;
Lee, JH ;
Menander, K ;
Chada, S ;
Gabrilovich, DI .
CLINICAL CANCER RESEARCH, 2006, 12 (03) :878-887
[3]   Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer [J].
Butts, C ;
Murray, N ;
Maksymiuk, A ;
Goss, G ;
Marshall, E ;
Soulières, D ;
Cormier, Y ;
Ellis, P ;
Price, A ;
Sawhney, R ;
Davis, M ;
Mansi, J ;
Smith, C ;
Vergidis, D ;
Ellis, P ;
MacNeil, M ;
Palmer, M .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (27) :6674-6681
[4]   Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma [J].
Carpentier, A ;
Laigle-Donadey, F ;
Zohar, S ;
Capelle, L ;
Behin, A ;
Tibi, A ;
Martin-Duverneuil, N ;
Sanson, M ;
Lacomblez, L ;
Taillibert, S ;
Puybasset, L ;
Van Effenterre, R ;
Delattre, JY ;
Carpentier, AF .
NEURO-ONCOLOGY, 2006, 8 (01) :60-66
[5]  
Carpentier AF, 1999, CANCER RES, V59, P5429
[6]   Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study [J].
Carpentier, Alexandre ;
Metellus, Philippe ;
Ursu, Renata ;
Zohar, Sarah ;
Lafitte, Francois ;
Barrie, Maryline ;
Meng, Yuxia ;
Richard, Margaretha ;
Parizot, Christophe ;
Laigle-Donadey, Florence ;
Gorochov, Guy ;
Psimaras, Dimitri ;
Sanson, Marc ;
Tibi, Annick ;
Chinot, Olivier ;
Carpentier, Antoine F. .
NEURO-ONCOLOGY, 2010, 12 (04) :401-408
[7]   External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing [J].
Chakraborty, M ;
Abrams, SI ;
Coleman, CN ;
Camphausen, K ;
Schlom, J ;
Hodge, JW .
CANCER RESEARCH, 2004, 64 (12) :4328-4337
[8]   Use of radiolabeled monoclonal antibody to enhance vaccine-mediated antitumor effects [J].
Chakraborty, Mala ;
Gelbard, Alexander ;
Carrasquillo, Jorge A. ;
Yu, Sarah ;
Mamede, Marcelo ;
Paik, Chang H. ;
Camphausen, Kevin ;
Schlom, Jeffrey ;
Hodge, James W. .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2008, 57 (08) :1173-1183
[9]   INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect [J].
Chiappori, Alberto A. ;
Soliman, Hatem ;
Janssen, William E. ;
Antonia, Scott J. ;
Gabrilovich, Dmitry I. .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2010, 10 (06) :983-991
[10]  
CHIBA I, 1990, ONCOGENE, V5, P1603